Avances en diabetes tipo 2

Laburpena

Diabetes mellitus type 2 is considered by the World Health Organization as one of the XXI Century epidemic. It increases the risk of cardiovascular disease, this being the first cause of mortality in these patients, preferably from ischemic heart disease and cerebral stroke, depending on a combination of specific risk factors , many of which are related to potentially avoidable factors such as hyperglycemia, obesity, smoking and hypertension. In order to corroborate the impact of glycemic intervention in cardiovascular disease, in recent years several clinical trials (VADT, ACCORD, ADVANCE, and UKPDS) have been made without conclusive results. Also, so far, ‘classic’ antidiabetics have shown good power in reaching HbA1c targets, but its cardiovascular protective effects are very poor. New drugs such as incretins may have potential cardioprotective effects, given the presence of GLP-1 receptors in different structures such as the heart, the peripheral vascular system and the adipocyte, although it requires long-term clinical trials to demonstrate these beneficial effects